SG11201508502RA - Monoclonal antibody directed against cxcr5 - Google Patents

Monoclonal antibody directed against cxcr5

Info

Publication number
SG11201508502RA
SG11201508502RA SG11201508502RA SG11201508502RA SG11201508502RA SG 11201508502R A SG11201508502R A SG 11201508502RA SG 11201508502R A SG11201508502R A SG 11201508502RA SG 11201508502R A SG11201508502R A SG 11201508502RA SG 11201508502R A SG11201508502R A SG 11201508502RA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
directed against
antibody directed
against cxcr5
cxcr5
Prior art date
Application number
SG11201508502RA
Inventor
Christine Power
Olivier Leger
Paul Bradfield
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of SG11201508502RA publication Critical patent/SG11201508502RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201508502RA 2013-05-02 2014-04-30 Monoclonal antibody directed against cxcr5 SG11201508502RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166251 2013-05-02
PCT/EP2014/058903 WO2014177652A1 (en) 2013-05-02 2014-04-30 Monoclonal antibody directed against cxcr5

Publications (1)

Publication Number Publication Date
SG11201508502RA true SG11201508502RA (en) 2015-11-27

Family

ID=48184103

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508502RA SG11201508502RA (en) 2013-05-02 2014-04-30 Monoclonal antibody directed against cxcr5

Country Status (14)

Country Link
US (1) US9534054B2 (en)
EP (1) EP2992014A1 (en)
JP (1) JP6522585B2 (en)
KR (1) KR20160003804A (en)
CN (1) CN105392802B (en)
AU (1) AU2014261398B2 (en)
BR (1) BR112015027388A2 (en)
CA (1) CA2909587A1 (en)
HK (1) HK1217340A1 (en)
MX (1) MX2015015232A (en)
RU (1) RU2015150723A (en)
SG (1) SG11201508502RA (en)
WO (1) WO2014177652A1 (en)
ZA (1) ZA201508081B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007641A (en) * 2016-12-21 2019-09-09 Bayer Pharma AG Antibody drug conjugates (adcs) having enzymatically cleavable groups.
FR3061716B1 (en) * 2017-01-06 2019-05-17 Elsalys Biotech NOVEL COMPOUNDS TARGETING CD160 HUMAN
EP3717516A1 (en) * 2017-12-01 2020-10-07 Pfizer Inc Anti-cxcr5 antibodies and compositions and uses thereof
BR112020025718A2 (en) * 2018-06-18 2021-04-06 Bayer Aktiengesellschaft BINDER / ACTIVE AGENT CONJUGATES TARGETED AGAINST CXCR5, HAVING ENZYMATICALLY CLIVABLE BINDERS AND ENHANCED ACTIVITY PROFILE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
UA117446C2 (en) * 2007-08-29 2018-08-10 Санофі-Авентіс HUMANIZED ANTIBODY TO CXCR5
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use

Also Published As

Publication number Publication date
WO2014177652A1 (en) 2014-11-06
BR112015027388A2 (en) 2017-08-29
JP6522585B2 (en) 2019-05-29
US9534054B2 (en) 2017-01-03
CA2909587A1 (en) 2014-11-06
RU2015150723A (en) 2017-06-07
ZA201508081B (en) 2017-09-27
AU2014261398B2 (en) 2019-08-29
US20160115235A1 (en) 2016-04-28
MX2015015232A (en) 2016-02-22
JP2016524595A (en) 2016-08-18
CN105392802B (en) 2019-09-03
EP2992014A1 (en) 2016-03-09
KR20160003804A (en) 2016-01-11
AU2014261398A1 (en) 2015-11-12
CN105392802A (en) 2016-03-09
HK1217340A1 (en) 2017-01-06

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti-fcrh5 antibodies
GB201322583D0 (en) Antibodies
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
HK1220142A1 (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti-ccl17 antibodies
HK1217340A1 (en) Monoclonal antibody directed against cxcr5 cxcr5
GB201312226D0 (en) Improved antibodies
HK1223950A1 (en) Monoclonal olfml-3 antibodies and uses thereof olfml-3
HK1215714A1 (en) Anti-() --methamphetamine monoclonal antibodies ()-
GB201318283D0 (en) Antibodies